This document compares properties of different thrombolytic drugs used to treat blood clots. It shows that rt-PA has high fibrin specificity and a short half-life, resulting in high patency rates of 75-85%. While streptokinase does not have fibrin specificity, it has a longer half-life of 20 hours but lower patency rates of 60-65%. Tenecteplase has the highest fibrin specificity and an even longer half-life of 20 hours, also resulting in high patency rates of 85%.
This document compares properties of different thrombolytic drugs used to treat blood clots. It shows that rt-PA has high fibrin specificity and a short half-life, resulting in high patency rates of 75-85%. While streptokinase does not have fibrin specificity, it has a longer half-life of 20 hours but lower patency rates of 60-65%. Tenecteplase has the highest fibrin specificity and an even longer half-life of 20 hours, also resulting in high patency rates of 85%.
This document compares properties of different thrombolytic drugs used to treat blood clots. It shows that rt-PA has high fibrin specificity and a short half-life, resulting in high patency rates of 75-85%. While streptokinase does not have fibrin specificity, it has a longer half-life of 20 hours but lower patency rates of 60-65%. Tenecteplase has the highest fibrin specificity and an even longer half-life of 20 hours, also resulting in high patency rates of 85%.